ArticlePhysiological reports2025
Collagenase treatment does not impair fiber contractile function in muscle biopsies from children with cerebral palsy.
Article in Physiological reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Collagenase treatment does not impair fiber contractile function in muscle biopsies from children with cerebral palsy.Physiological reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cerebral palsy (CP) often presents with increased passive stiffness of the skeletal muscles, primarily due to increased collagen in the extracellular matrix. Collagenase from Clostridium histolyticum (CCH), an enzyme that degrades collagen, is used clinically to treat fibrotic conditions such as Dupuytren's contracture and Peyronie's disease. Although prior work demonstrated reduced passive stiffness in muscle bundles from children with CP following CCH incubation, its effects on active contractile properties remain unknown. Thus, this study was aimed at investigating the maximal active force, calcium sensitivity, and myofibrillar protein content (myosin and actin) after CCH incubation. Nine muscle biopsies from children with CP were used for skinned fiber mechanical testing at an average sarcomere length of 2.4 μm, and for myosin and actin analysis using 12% SDS-PAGE. Maximal active stress (control 59.8 ± 24.2 kPa; CCH 63.2 ± 24.5 kPa; p = 0.51) and pCa₅₀ (control 6.04 ± 0.10; CCH 5.99 ± 0.18; p = 0.43) did not significantly differ. Similarly, the normalized myosin (control 1.000 ± 0.167, CCH 1.004 ± 0.178; p = 0.93) and actin (control 1.000 ± 0.336, CCH 1.107 ± 0.330; p = 0.231) content did not differ between conditions. These results suggest that collagenase does not impair the contractile function in muscle fibers from children with CP and thus might be a feasible treatment to reduce stiffness due to muscle fibrosis. Research into whole-muscle force transmission following collagenase treatment is needed to evaluate its clinical viability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.